Skip Navigation

National Institutes of Health

Clinical Center, Building 10
9000 Rockville Pike
Bethesda, MD 20892
(301) 496-4000
http://www.nih.gov

Number of Transplants Performed

This center has been performing allogeneic transplants since 1992 and has been an NMDP transplant center since March 2007.

Transplants Reported (From Jan. 2011 to Dec. 2012 as reported by the centers)       Unrelated or Related Donor Auto-
logous

(PBSC or marrow)
Total (by transplant type)
Marrow PBSC Cord
Blood
Unrelated Donor
- Adult
3 31 10 --- 44
Unrelated Donor
- Pediatric
0 11 5 --- 16
Related Donor
- Adult
6 109 0 --- 115
Related Donor
- Pediatric
0 5 0 --- 5
Autologous
- Adult
--- --- --- 7 7
Autologous
- Pediatric
--- --- --- 0 0
Total
(by cell source)
9 156 15 7 187

To find centers that perform cord blood transplants, use the Search Tool on this site.


Patient Survival Information for this Center

NCI Experimental Transplantation and Immunology Branch (Related Donor Program)


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 61 patients.

The actual 1-year survival of these patients is 67.2%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 49.6% and 72.0%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).

National Heart Lung & Blood Institute


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 34 patients.

The actual 1-year survival of these patients is 79.3%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 62.4% and 89.8%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).

NCI Related Donor Program


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 2 patients.

The actual 1-year survival of these patients is 0.0%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 0.0% and 92.7%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).

National Institutes of Allergy & Infectious Disease


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 3 patients.

The actual 1-year survival of these patients is 100.0%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 38.6% and 100.0%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).

NCI Matched Unrelated Donor Program


This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

  1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2009, 2010 and 2011, and
  2. Who had their transplant at a U.S. transplant center, and
  3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 94 patients.

The actual 1-year survival of these patients is 67.0%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 62.2% and 79.7%.

For help with understanding these statistics, please see Understanding Transplant Outcomes (PDF).


Transplant Results by Patient's Age, Disease Type and Stage

NCI Experimental Transplantation and Immunology Branch - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- 1/1 -- -- -- -- -- 1/1
Acute myelogenous leukemia in second complete remission -- -- 1/1 -- -- -- -- 1/1
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 1/1 1/1 0/1 2/3
Chronic myelogenous leukemia in accelerated phase or second chronic phase -- -- -- 1/1 -- -- 1/1 2/2
Disorders of the immune system -- -- -- 2/2 1/1 -- -- 3/3
Hodgkin lymphoma -- -- 2/3 1/1 -- -- -- 3/4
Multiple myeloma / Plasma cell disorder -- -- -- -- 1/1 1/1 1/2 3/4
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- -- 1/1 1/1 -- 2/2
Myeloproliferative syndromes -- -- -- -- -- -- 1/1 1/1
Non-Hodgkin lymphoma -- -- 1/2 1/1 7/8 4/9 3/4 16/24
Other acute leukemia -- -- -- -- 0/1 2/2 -- 2/3
Solid tumors / Other malignancies -- -- -- -- 0/1 1/5 1/4 2/10
Total -- 1/1 4/6 5/5 11/14 10/19 7/13 38/58

National Heart Lung & Blood Institute - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- -- 1/1 -- 0/1 1/1 2/3
Acute lymphoblastic leukemia in second complete remission -- -- 1/1 -- -- -- -- 1/1
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- -- 1/1 -- -- 1/1
Acute myelogenous leukemia in first complete remission -- -- 0/1 -- -- -- -- 0/1
Acute myelogenous leukemia in second complete remission -- -- 0/1 -- 2/2 -- -- 2/3
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- -- 1/3 -- 1/1 2/4
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- -- 2/2 -- 2/2
Inherited abnormalities of erythrocyte differentiation or function -- 1/1 1/1 2/2 1/2 -- -- 5/6
Non-Hodgkin lymphoma -- -- -- -- 1/1 -- 1/1 2/2
Severe aplastic anemia -- 2/2 1/2 1/1 1/1 -- -- 5/6
Total -- 3/3 3/6 4/4 7/10 2/3 3/3 22/29

NCI Related Donor Program

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Solid tumors / Other malignancies -- -- 0/1 0/1 -- -- -- 0/2
Total -- -- 0/1 0/1 -- -- -- 0/2

National Institutes of Allergy & Infectious Disease - Related

Survival by Patient's Age, Disease Type and Stage after Related Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using related donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Disorders of the immune system 2/2 -- 1/1 -- -- -- -- 3/3
Total 2/2 -- 1/1 -- -- -- -- 3/3

NCI Matched Unrelated Donor Program - Unrelated

Survival by Patient's Age, Disease Type and Stage after Unrelated Donor Transplantation

This report is based on first allogeneic transplants performed between January 2009 and December 2011 using unrelated donors. It only includes patients with known survival status at 1-year post-transplant. In some cases, patients may have been alive at last reported follow-up that was less than one year. Those patients have not been included in this report. The first number represents the number of patients alive at one year post transplant. The second number is a total number of transplanted patients in that particular group.


Diagnosis 0-9 Yrs 10-19 Yrs 20-29 Yrs 30-39 Yrs 40-49 Yrs 50-59 Yrs 60+ Yrs Overall
Acute lymphoblastic leukemia in first complete remission -- -- -- -- 0/1 -- -- 0/1
Acute lymphoblastic leukemia in second complete remission -- -- 0/1 2/2 -- -- -- 2/3
Acute lymphoblastic leukemia in third or higher complete remission, relapse, or primary induction failure -- -- 1/1 0/1 -- -- -- 1/2
Acute myelogenous leukemia in first complete remission -- -- -- -- -- 0/1 -- 0/1
Acute myelogenous leukemia in second complete remission -- 1/1 -- -- 0/1 -- -- 1/2
Acute myelogenous leukemia in third or higher complete remission, relapse, or primary induction failure -- -- -- -- 0/1 -- -- 0/1
Chronic lymphocytic leukemia and other chronic leukemia -- -- -- -- 2/5 3/3 2/5 7/13
Chronic myelogenous leukemia in first chronic phase -- -- -- 1/1 1/1 -- -- 2/2
Disorders of the immune system 6/6 5/7 2/4 1/1 1/1 -- -- 15/19
Hodgkin lymphoma -- -- 2/2 2/3 0/1 -- -- 4/6
Multiple myeloma / Plasma cell disorder -- -- -- 0/1 1/1 -- -- 1/2
Myelodysplastic disorders - Refractory anemia, Refractory anemia with ringed sideroblast, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with multilineage dysplasia and ringed sideroblast -- -- 1/1 -- -- -- -- 1/1
Myelodysplastic disorders - Refractory Anemia with excess blasts (with 5-9% brasts (RAEB-1) and 10-19% blasts (RAEB-2)) -- -- -- 1/1 -- -- -- 1/1
Myelodysplastic disorders - Other MDS -- -- 1/2 -- 1/1 -- 1/1 3/4
Myeloproliferative syndromes -- -- -- -- -- 0/1 -- 0/1
Non-Hodgkin lymphoma -- -- 0/2 0/2 5/6 4/5 4/7 13/22
Other acute leukemia -- -- -- -- -- 1/1 -- 1/1
Severe aplastic anemia 1/1 3/3 3/3 -- -- -- -- 7/7
Solid tumors / Other malignancies -- -- -- 0/1 -- -- -- 0/1
Total 7/7 9/11 10/16 7/13 11/19 8/11 7/13 59/90

Program Description:

This NIH Clinical Center program supports innovative transplant approaches conducted by three NIH Institutes (NCI, NIAID, and NHLBI). To undergo a transplant, patients must be enrolled in an active clinical trial at one of these institutes.

Contact Information:

If you have transplant-related questions, please contact Jennifer Wilder, transplant center coordinator, at (301) 451-3722 or by e-mail at wilderj@mail.nih.gov.

Program Type:

Adult and Pediatric

Attending Physicians:

(Medical Doctors)

Adult -

George Aue, John Barrett, Minoo Battiwalla, Charles Bolan, Richard Childs, Cynthia Dunbar, Courtney Fitzhugh, Daniel Fowler, Ronald Gress, David Halverson, Dennis Hickstein, Matthew Hsieh, Elizabeth Kang, Harry Malech, Steven Pavletic, Ito Sawa, John Tisdale, Danielle Townsley, Adrian Wiestner, Kirsten Williams

Pediatric -

Richard Childs, Courtney Fitzhugh, Jason Levin, Crystal Mackall, Alan Wayne, Kirsten Williams

Transplants Performed:

Marrow/PBSC, single cord, and double cord

Cord blood transplants performed on:

Adult and pediatric

Find research trials at this center here:

ClinicalTrials.gov

Estimated Search & Transplant Costs

The costs for a transplant vary greatly from center to center and depend on factors such as health insurance, disease type and disease stage of the patient, as well as center-specific billing policies. Examples of costs in the search and transplant include:

  • The amount and geographic location of donors tested
  • Testing needed to confirm a match
  • Processing and collecting of tissue-typing samples
  • Donor workup testing needed
  • Getting the marrow, PBSC or cord blood unit for transplant

For the best understanding of costs of transplant and follow-up for a specific transplant center, contact the center's Financial Representative.

help Explain Transplant Costs at Different Centers

Resources for financial information

If you have questions about costs and financial services at this transplant center, you can contact the center's financial representative, Elaine Ayres by e-mail at eayres@mail.nih.gov or by phone at (301) 594-3019.

Financial services at this center could include:

  • Health insurance information
  • Financial assistance
  • Patient-related resources

Additional Information

Further information about this center, including the number and type of transplants performed in each of the last three years, and the support groups offered, may be found in the BMT InfoNet Transplant Center Directory:
http://www.bmtinfonet.org/transplantcenters.

BMT InfoNet (Blood & Marrow Transplant Information Network) is a nonprofit organization that provides information and emotional support to transplant patients and their families.